Goldman initiated coverage on Altimmune with a new price target
$ALT
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman initiated coverage of Altimmune with a rating of Neutral and set a new price target of $13.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2025 | Mkt Perform | William Blair | |
| 1/8/2025 | $18.00 | Buy | Stifel |
| 11/12/2024 | $26.00 | Buy | UBS |
| 4/29/2024 | Buy → Neutral | Guggenheim | |
| 1/24/2024 | $13.00 | Neutral | Goldman |
| 3/22/2023 | $20.00 → $6.00 | Buy → Neutral | Goldman |
| 12/1/2022 | $20.00 | Buy | Goldman |
| 12/29/2021 | $30.00 | Buy | Jefferies |
4 - Altimmune, Inc. (0001326190) (Issuer)
4 - Altimmune, Inc. (0001326190) (Issuer)
SCHEDULE 13G/A - Altimmune, Inc. (0001326190) (Subject)
10-Q - Altimmune, Inc. (0001326190) (Filer)
8-K - Altimmune, Inc. (0001326190) (Filer)